Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus subcutaneous methotrexate for severe psoriasis
IRCT20231010059674N1Phase 4Completed
- Sponsor
- National University of Medical Sciences
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate in psoriasis (2 arms), sponsored by National University of Medical Sciences. Primary endpoints: Psoriasis Global Assessment score, Adverse effects and 5 more. Started May 2024; status: completed.
02
Drugs
methotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20231010059674N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231010059674N1.